The univariate analysis revealed a significantly higher number of male individuals and individuals with diabetes mellitus, chronic kidney disease, ischemic heart disease, peripheral artery disease, and a higher Charlson comorbidity index among P2Y12 inhibitor users. Here, P2RY12 is linked to peripheral arterial disease.